GT201500251A - Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico - Google Patents

Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico

Info

Publication number
GT201500251A
GT201500251A GT201500251A GT201500251A GT201500251A GT 201500251 A GT201500251 A GT 201500251A GT 201500251 A GT201500251 A GT 201500251A GT 201500251 A GT201500251 A GT 201500251A GT 201500251 A GT201500251 A GT 201500251A
Authority
GT
Guatemala
Prior art keywords
muted
forms
kinazolinic
inhibitors
activate
Prior art date
Application number
GT201500251A
Other languages
English (en)
Inventor
David Yunzhi Li
Jiabing Wang
Zhenfan Yang
Qingbei Zeng
Xiaolin Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of GT201500251A publication Critical patent/GT201500251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMLA I O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, QUE POSEEN ACTIVIDAD INHIBITORIA FRENTE A FORMAS MUTADAS ACTIVANTES DE EGFR Y QUE SON, POR CONSIGUIENTE, ÚTILES POR SU ACTIVIDAD CONTRA EL CÁNCER Y EN MÉTODOS DE TRATAMIENTO DEL CUERPO HUMANO O ANIMAL. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A SU USO EN LA ELABORACIÓN DE MEDICAMENTOS PARA EMPLEAR EN LA PRODUCCIÓN DE UN EFECTO CONTRA EL CÁNCER EN UN ANIMAL DE SANGRE CALIENTE TAL COMO UN SER HUMANO.
GT201500251A 2013-03-06 2015-09-04 Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico GT201500251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06

Publications (1)

Publication Number Publication Date
GT201500251A true GT201500251A (es) 2017-10-09

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500251A GT201500251A (es) 2013-03-06 2015-09-04 Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico

Country Status (42)

Country Link
US (4) US9066979B2 (es)
EP (2) EP3342770B1 (es)
JP (1) JP5894714B1 (es)
KR (1) KR101645112B1 (es)
CN (1) CN105209456B (es)
AP (1) AP2015008696A0 (es)
AR (1) AR095039A1 (es)
AU (1) AU2014224382B2 (es)
BR (1) BR112015020787B1 (es)
CA (1) CA2901269C (es)
CL (1) CL2015002361A1 (es)
CR (1) CR20150450A (es)
CY (1) CY1119487T1 (es)
DK (1) DK2964638T3 (es)
DO (1) DOP2015000189A (es)
ES (1) ES2642201T3 (es)
GT (1) GT201500251A (es)
HK (1) HK1216315A1 (es)
HR (1) HRP20171689T1 (es)
HU (1) HUE034568T2 (es)
IL (1) IL240578B (es)
LT (1) LT2964638T (es)
MA (1) MA38380A1 (es)
ME (1) ME03041B (es)
MX (1) MX362247B (es)
MY (1) MY186126A (es)
NI (1) NI201500123A (es)
NO (1) NO2964638T3 (es)
PE (1) PE20152000A1 (es)
PH (1) PH12015501965B1 (es)
PL (1) PL2964638T3 (es)
PT (1) PT2964638T (es)
RS (1) RS56566B1 (es)
RU (1) RU2656597C2 (es)
SG (1) SG11201506487YA (es)
SI (1) SI2964638T1 (es)
TN (1) TN2015000368A1 (es)
TW (1) TWI543977B (es)
UA (1) UA115686C2 (es)
UY (1) UY35369A (es)
WO (1) WO2014135876A1 (es)
ZA (1) ZA201507353B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2656597C2 (ru) * 2013-03-06 2018-06-06 Астразенека Аб Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
US20170050936A1 (en) 2013-08-23 2017-02-23 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP3201190A4 (en) * 2014-10-01 2018-03-14 Sun Pharmaceutical Industries Ltd Crystalline form of afatinib dimaleate
CN107613769A (zh) 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
CN105859641B (zh) 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物b晶型及其制备方法
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物a晶型及其制备方法
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
EP3749310A4 (en) * 2018-02-08 2021-08-18 Neupharma, Inc. CERTAIN CHEMICAL SUBSTANCES, COMPOSITIONS AND PROCEDURES
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
SG11202101712XA (en) * 2018-09-14 2021-04-29 Spectrum Pharmaceuticals Inc Kits and methods for treating cancers
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
MA55508A (fr) 2019-03-29 2022-02-09 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2384282A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
BR0308902A (pt) * 2002-03-30 2005-01-04 Boehringer Ingelheim Pharma 4-(n-fenilamino)-quinazolinas/quinolinas como inibidoras da tirosina cinase
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
UY28441A1 (es) 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
CA2541100A1 (en) 2003-09-16 2005-03-24 Astrazenca Ab Quinazoline derivatives
ES2281007T3 (es) 2003-09-19 2007-09-16 Astrazeneca Ab Derivados de quinazolina.
EP1667992B1 (en) 2003-09-19 2007-01-24 Astrazeneca AB Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
WO2005094357A2 (en) 2004-03-31 2005-10-13 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
WO2006119676A1 (fr) * 2005-05-12 2006-11-16 Wenlin Huang Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale
CN101175732B (zh) * 2005-05-12 2010-06-16 黄文林 一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
US20100234371A1 (en) 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
US8648087B2 (en) * 2005-11-15 2014-02-11 Array Biopharma, Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (en) 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
PL3511330T3 (pl) 2009-12-31 2021-04-19 Hutchison Medipharma Limited Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
PE20131403A1 (es) 2010-08-23 2014-01-10 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
RU2656597C2 (ru) * 2013-03-06 2018-06-06 Астразенека Аб Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста

Also Published As

Publication number Publication date
EP2964638A1 (en) 2016-01-13
CY1119487T1 (el) 2018-03-07
MX2015011818A (es) 2016-01-08
EP2964638B1 (en) 2017-08-09
AP2015008696A0 (en) 2015-08-31
TN2015000368A1 (en) 2017-01-03
EP3342770B1 (en) 2022-03-30
HRP20171689T1 (hr) 2018-02-23
CN105209456A (zh) 2015-12-30
UA115686C2 (uk) 2017-12-11
NI201500123A (es) 2016-02-16
AR095039A1 (es) 2015-09-16
KR101645112B1 (ko) 2016-08-02
PT2964638T (pt) 2017-11-14
US20150320751A1 (en) 2015-11-12
TWI543977B (zh) 2016-08-01
NZ710850A (en) 2020-09-25
DOP2015000189A (es) 2015-08-31
CL2015002361A1 (es) 2016-01-04
BR112015020787A2 (pt) 2017-07-18
LT2964638T (lt) 2017-12-27
US20160340342A1 (en) 2016-11-24
DK2964638T3 (en) 2017-10-30
AU2014224382A1 (en) 2015-09-03
SG11201506487YA (en) 2015-09-29
SI2964638T1 (sl) 2017-11-30
MY186126A (en) 2021-06-24
PH12015501965A1 (en) 2016-01-11
ME03041B (me) 2018-10-20
HK1216315A1 (zh) 2016-11-04
BR112015020787B1 (pt) 2022-12-06
PE20152000A1 (es) 2016-01-22
CA2901269A1 (en) 2014-09-12
IL240578A0 (en) 2015-09-24
JP5894714B1 (ja) 2016-03-30
US20180016259A1 (en) 2018-01-18
CA2901269C (en) 2022-01-18
KR20150083782A (ko) 2015-07-20
UY35369A (es) 2014-08-29
NO2964638T3 (es) 2018-01-06
US9066979B2 (en) 2015-06-30
RS56566B1 (sr) 2018-02-28
TW201520206A (zh) 2015-06-01
ZA201507353B (en) 2017-03-29
AU2014224382B2 (en) 2016-11-10
MA38380A1 (fr) 2017-01-31
HUE034568T2 (en) 2018-02-28
EP3342770A1 (en) 2018-07-04
US9718806B2 (en) 2017-08-01
ES2642201T3 (es) 2017-11-15
RU2015139513A (ru) 2017-04-10
MX362247B (es) 2019-01-09
PH12015501965B1 (en) 2016-01-11
IL240578B (en) 2019-03-31
JP2016511225A (ja) 2016-04-14
CR20150450A (es) 2015-12-01
RU2656597C2 (ru) 2018-06-06
US20140255428A1 (en) 2014-09-11
WO2014135876A1 (en) 2014-09-12
US9375432B2 (en) 2016-06-28
PL2964638T3 (pl) 2018-01-31
CN105209456B (zh) 2018-05-08

Similar Documents

Publication Publication Date Title
GT201500251A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
ECSP17039611A (es) Derivados de quinazolina utilizados para tratar el vih
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
GT201400196A (es) Compuestos de heterociclilo
CL2016001895A1 (es) Compuestos
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
ECSP15014941A (es) Compuestos antivíricos para el vsr
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
UY35747A (es) Derivados sustituidos de fenilalanina
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
UY35745A (es) Derivados sustituidos de fenilalanina
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
ECSP16096831A (es) Derivados de naftiridinadiona